Arcturus Therapeutics, Inc., a San Diego-based developer of RNAi technologies for the treatment of rare diseases, raised $1.3m in seed funding.
The round was led by high net-worth private investors from the United States and Canada.
The company intends to use the funding for the purchase of capital equipment and further development of its intellectual property of RNAi delivery technologies, along with RNAi target selection, design and in vitro proof of concept studies.
Founded in 2013 by Joseph E. Payne, president and CEO, and Pad Chivukula, Arcturus Therapeutics focuses on the discovery and development of therapeutic modalities to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment.
The company is located in San Diego-based Janssen Labs.